Travers Smith has acted as lead counsel for Medicxi on the fundraising for Medicxi Growth I LP, a new $300 million fund that will focus on growth stage companies in European life sciences.
With this new late stage fund, Medicxi will help fill a clear gap in Europe, where talented life sciences entrepreneurs do not have access to as much local financial support as their US-based counterparts to expand exciting opportunities into more mature companies.
Medicxi Growth I is a continuation of Medicxi’s pioneering ‘asset-centric’ investment strategy and will be looking to invest in private or public companies with at least one asset in Phase II or beyond that Medicxi believes can become a licenced pharmaceutical product, meeting unmet medical needs.
The Travers Smith team was led by Head of Investment Funds Sam Kay, with support from Funds Associate Eilidh Campbell. Tax advice was provided by Tax Partner Emily Clark and Associate Tom Rickford.
Speaking about the fundraising Sam Kay said: “We are delighted to have assisted Medicxi on the successful fundraising for Medicxi Growth I LP and it is really exciting to see the fund being supported by heavyweight strategic investors such as the European Investment Fund.”